BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

483.85M

Vuru Grade

23.50/100

Current Price

$6.56
-0.02 (-0.30%)

Company Metrics

  • P/E 0
  • P/S 22.09
  • P/B 121.85
  • EPS -0.94
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / 0%
  • Avg. Vol. 932,936.00
  • Shares 73.76M
  • Market Cap. 483.85M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July
Motley Fool - Aug 11, 2016
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company primarily focused on small-molecule drugs that block enzymes associated with disease development, leaped 27% in July, according to data from S&P Global Market ...
BioCryst A High Risk Reward Stock
Seeking Alpha - Feb 17, 2017
Shares of BioCryst (NASDAQ:BCRX) have been volatile. Shares have traded as low as $5.72 to over $6.70 in the last seven sessions.
BioCryst Pharmaceuticals Inc. (BCRX) Soars 6.82% on February 16
Equities.com - Feb 16, 2017
BioCryst Pharmaceuticals Inc. (BCRX) had a good day on the market for Thursday February 16 as shares jumped 6.82% to close at $6.58.
Stock Returns: BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) versus Momenta ... - CML News
Analyst Activity – Ladenburg Thalmann Financial Services Initiates Coverage On ... - Market Exclusive
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2016 Results ...
Seeking Alpha - Aug 5, 2016
Good day, ladies and gentlemen. Welcome to the BioCryst Second Quarter 2016 Conference Call. At this time, all participants are in a listen-only mode.
BioCryst Pharmaceuticals Inc. (BCRX) Plunges 5.67% on February 10
Equities.com - Feb 10, 2017
BioCryst Pharmaceuticals Inc. (BCRX) had a rough trading day for Friday February 10 as shares tumbled 5.67%, or a loss of $-0.34 per share, to close at $5.66.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Close to Lift Curtain on June ... - The Voice Registrar
BioCryst Pharmaceuticals Inc. (BCRX) Plunges 5.18% on February 02
Equities.com - Feb 2, 2017
BioCryst Pharmaceuticals Inc. (BCRX) had a rough trading day for Thursday February 02 as shares tumbled 5.18%, or a loss of $-0.32 per share, to close at $5.86.
Biocryst Where To From Here?
Seeking Alpha - Aug 9, 2016
Sixth months ago I wrote about Biocryst (NASDAQ:BCRX) as its share price crashed to $1.78 (it went on to trade as low as $1.66) after its Phase 2 OPuS-2 clinical trial for treatment of Hereditary AngioEdema (NYSE:HAE) failed to meet its primary ...
BioCryst Pharmaceuticals Inc. (BCRX) Soars 5.57% on January 24
Equities.com - Jan 24, 2017
BioCryst Pharmaceuticals Inc. (BCRX) had a good day on the market for Tuesday January 24 as shares jumped 5.57% to close at $6.25.
FBR & Co Reiterates “Outperform” Rating for BioCryst Pharmaceuticals, Inc. (BCRX) - The Cerbat Gem
BioCryst Pharmaceuticals, Inc. (BCRX) Given Outperform Rating at FBR & Co - Sports Perspectives
Option Market: BioCryst Pharmaceuticals Inc Risk Hits An Extreme High
CML News - Feb 10, 2017
We're going to look at a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for BioCryst Pharmaceuticals ...
BioCryst Pharmaceuticals Inc. (BCRX) Plunges 6.36% on January 30
Equities.com - Jan 30, 2017
BioCryst Pharmaceuticals Inc. (BCRX) had a rough trading day for Monday January 30 as shares tumbled 6.36%, or a loss of $-0.41 per share, to close at $6.04.
BioCryst Pharma (BCRX) Says EMA Accepts Peramivir MAA Filing - StreetInsider.com
European drug agency to review BioCryst flu treatment - WRAL Tech Wire
Growth Rate Assumed by Market

We did a reverse valuation to calculate the growth rate the market is assuming for BCRX to be considered fairly valued at its current market price. It's useful to compare this to the growth rate we're assuming for the Growth Price.

Future Free Cash Flow Growth Rate

This is the annual growth rate we've applied to calculate BCRX's Free Cash Flow for the next 10 years. To calculate it, we looked at several time periods of the last 10 years. Feel free to adjust it, but we limit the initial growth rate to 20% and slow it down over the years. Otherwise, long-term sustainability issues come into play.

Discount Rate

The discount rate is the annual rate of return an investor requires to take the risk of investing in a single stock. To account for that risk, this should be above 8-10%, as this is the avg. annual rate of return for the S&P500 over the past 100 years.

$6.56 Current Price

$-0.94 Growth Price (DCF)

Why is this negative?


Show Free Cash Flow numbers

$-54.73 Book Price

Overvalued by 934.29%


Very Poor Cash Return on Invested Capital over the past 5 years

BCRX has failed to generate positive returns on its investments in buildings, projects and equipment. This could be due to poor management, lack of an economic moat or the capital intensive nature of the business.

BCRX has lost $251.78 of cash for every $100 invested.
Figures in USD. Fiscal year ends in December
20112012201320142015
Free Cash Flow -32.31M -37.51M -26.56M -38.66M -18.24M
divided by
Invested Capital 14.19M 4.62M -4.45M 6.42M 8.54M
Cash ROIC -227.65% -812.61% 597.53% -602.60% -213.58%

Very Poor Return on Equity over the past 5 years

BCRX has shown an inability to deliver results for shareholders. This could be due to poor management, BCRX operating in a highly competitive industry, or having a weak business in general.

BCRX has generated a $106.90 loss for every $100 of Shareholders' Equity.
Figures in USD. Fiscal year ends in December
20112012201320142015
Net Income -56.95M -39.08M -30.11M -45.19M -43.02M
divided by
Stockholders' Equity 14.81M -454,000.00 -1.13M 75.64M 47.72M
Return on Equity -384.63% - - -59.75% -90.14%

Poor Business Performance over the past 10 years

BCRX's inability to produce positive free cash flow for the majority of the past 10 years is concerning. It should be a red flag, since this company does not have a track record of delivering results for shareholders. This could be due to poor management or the nature of its business.

BCRX has been losing money for the majority of the past 10 years.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Free Cash Flow -16.75M -25.00M -22.09M -16.82M -28.88M -32.31M -37.51M -26.56M -38.66M -18.24M

Weak Balance Sheet

BCRX's financial position is not ideal. The key is to check whether BCRX is using debt to fuel its growth and the sustainability of that tendency. Highly capital intensive businesses (see Economic Moat) follow this route, which can deeply impact the future prospects of the business.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Cash 37.46M 50.70M 61.53M 68.96M 53.95M 41.72M 35.60M 38.06M 72.77M 51.56M
Current Assets 45.79M 91.70M 75.02M 111.02M 87.42M 52.86M 41.98M 42.12M 89.34M 65.99M
Total Assets 68.49M 142.72M 84.69M 142.19M 109.45M 82.21M 57.44M 48.87M 136.87M 124.56M
Current Liabilities 10.73M 28.12M 17.11M 37.25M 27.82M 26.30M 17.22M 15.26M 57.69M 64.45M
Total Liabilities 47.33M 77.81M 38.27M 55.92M 43.94M 67.40M 57.89M 49.99M 61.24M 76.83M
Stockholder' Equity 21.16M 64.91M 46.43M 86.27M 65.50M 14.81M -454,000.00 -1.13M 75.64M 47.72M
Current Ratio 4.27 3.26 4.39 2.98 3.14 2.01 2.44 2.76 1.55 1.02
TL-to-TA 0.69 0.55 0.45 0.39 0.40 0.82 1.01 1.02 0.45 0.62

Low or No Reinvestment of Profits over the past 10 years

BCRX has either been retaining a small amount of their earnings or has done so inconsistently. A lack of consistency could be due to BCRX operating at a loss or them having such a strong economic moat they feel comfortable spending profits on growth. Be wary of future prospects and if applicable, inspect the moat's sustainability.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Retained Earnings -195.48M -224.54M -249.27M -262.72M -296.57M -353.52M -392.60M -422.71M -467.90M -510.92M
Retained Earnings Growth - -14.86% -11.01% -5.40% -12.89% -19.20% -11.05% -7.67% -10.69% -9.19%

Erratic Net Profit Margins over the past 10 years

BCRX has had highly erratic net profit margins which are a great cause for concern. This company may operate in a highly volatile industry, or it may just have poor performance. Look at reasons for this inconsistency to understand if there is any reason to look past it.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Net Income -43.62M -29.06M -24.73M -13.45M -33.85M -56.95M -39.08M -30.11M -45.19M -43.02M
divided by
Revenue 6.21M 71.24M 56.56M 74.59M 62.38M 19.64M 26.29M 17.33M 13.61M 48.26M
Net Profit Margin -702.16% -40.79% -43.73% -18.03% -54.27% -289.91% -148.64% -173.72% -332.08% -89.15%

Strong Pricing Power over the past 10 years

BCRX has maintained substantial gross margins, suggesting that they have been able to set prices without consideration of the cost of goods sold. This potentially leaves flexibility in inflationary environments to raise prices on consumers and maintain profitability.

$98.79 of every $100 worth of sales have been Gross Profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Gross Profit 6.21M 71.24M 56.56M 70.05M 62.29M 19.64M 26.16M 17.23M 13.49M 46.36M
divided by
Revenue 6.21M 71.24M 56.56M 74.59M 62.38M 19.64M 26.29M 17.33M 13.61M 48.26M
Gross Margin 100.00% 100.00% 100.00% 93.91% 99.86% 100.00% 99.50% 99.43% 99.10% 96.07%

Low Capital Intensity over the past 10 years

BCRX has consistently used a small portion of their Net Income buying new equipment or investing in new facilities. This indicates that BCRX may require minimal investment to stay competitive. This leaves them with extra money to spend on growing their business and potentially buying back stock.

-% of Profits are being spent on Capital Expenditures, like Property, Plant, & Equipment, required to run the business.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Capital Expenditure 1.53M - 1.21M 603,692.00 324,764.00 55,000.00 113,000.00 30,000.00 106,000.00 5.12M
divided by
Net Income -43.62M -29.06M -24.73M -13.45M -33.85M -56.95M -39.08M -30.11M -45.19M -43.02M
Capital Expenditure Ratio -3.52% - -4.90% -4.49% -0.96% -0.10% -0.29% -0.10% -0.23% -11.91%

No Dividend History over the past 10 years

BCRX has never distributed dividends or has recently suspended their dividend distribution.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Dividend Paid - - - - - - - - - -
divided by
Shares Outstanding 29.15M 32.77M 38.06M 38.93M 44.56M 45.14M 49.47M 55.22M 66.77M 72.90M
Dividend Paid Per Share - - - - - - - - - -
Price at Year End 11.56 5.89 1.19 6.44 5.13 2.47 1.40 7.64 12.10 10.49
Dividend Yield - - - - - - - - - -

No History of Stock Buybacks over the past 10 years

We're neutral on this. It's not necessarily good or bad that BCRX hasn't initiated a stock buyback.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Shares Outstanding 29.15M 32.77M 38.06M 38.93M 44.56M 45.14M 49.47M 55.22M 66.77M 72.90M
Stock Bought Back - -11.06% -13.90% -2.22% -12.65% -1.28% -8.75% -10.40% -17.31% -8.41%
Share your thoughts about BCRX

Sign Up or Log In to start contributing!


Discussion

Nothing here yet. Be the first to post!